Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium.

OBJECTIVE To ascertain the progress being made towards the implementation of stereotactic ablative body radiotherapy (SABR) treatment in the UK, to obtain details of current practice in centres with an active treatment programme and to assess the projected future provision. METHODS In August 2012, an online questionnaire was sent to all 65 UK radiotherapy institutions. The included questions covered the current number of patients being treated and the intended number of patients for each clinical site; immobilization and motion management methods; CT scanning protocols; target and organ-at-risk delineation; treatment planning; image-guidance and treatment protocols; and quality assurance methods. RESULTS 48/65 (74%) institutions responded by the end of November 2012, with 15 indicating an active SABR programme. A further four centres indicated that a SABR protocol had been established but was not yet in clinical use. 14 of the 29 remaining responses stated an intention to develop a SABR programme in the next 2 years. CONCLUSION The survey responses confirm that SABR provision in the UK is increasing and that this should be expected to continue in the next 2 years. A projection of the future uptake would suggest that by the end of 2014, UK SABR provision will be broadly in line with international practice.

[1]  A. Louie,et al.  Surgery versus SABR for NSCLC. , 2013, The Lancet. Oncology.

[2]  M. Lodge,et al.  Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  S. Senan,et al.  Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  G. Webster,et al.  Stereotactic ablative radiotherapy in the UK: current status and developments. , 2013, The British journal of radiology.

[5]  Joe Y. Chang,et al.  Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? , 2013, Thoracic surgery clinics.

[6]  S. Senan,et al.  Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? , 2013, The Lancet. Oncology.

[7]  Suresh Senan,et al.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  M. Daly,et al.  Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  B. Loo,et al.  American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. , 2012, Chest.

[10]  Matthew B. Podgorsak,et al.  A dosimetric evaluation of VMAT for the treatment of non‐small cell lung cancer , 2012, Journal of applied clinical medical physics.

[11]  R. Rowe.  NHS Commissioning Board , 2012 .

[12]  Michael Lock,et al.  Radiotherapy for liver metastases: a review of evidence. , 2012, International journal of radiation oncology, biology, physics.

[13]  C. Clark,et al.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice. , 2011, The British journal of radiology.

[14]  Joshua D. Lawson,et al.  A survey of stereotactic body radiotherapy use in the United States , 2011, Cancer.

[15]  Suresh Senan,et al.  Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  A. Martin,et al.  Stereotactic body radiotherapy: a review. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  Mark K Buyyounouski,et al.  Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. , 2010, International journal of radiation oncology, biology, physics.

[18]  H. Shirato,et al.  Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. , 2009, International journal of radiation oncology, biology, physics.

[19]  S. Senan,et al.  Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Joachim Widder,et al.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study , 2009, Radiation oncology.

[21]  J. Galvin,et al.  Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early Stage Lung Cancer Patients , 2007 .

[22]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.